Search for content, post, videos

Boehringer Ingelheim takes its first step into gene therapy

Boehringer Ingelheim office
The company have together with the UK Cystic Fibrosis Gene Therapy Consortium (GTC), consisting of Imperial College London and the Universities of Oxford and Edinburgh, Imperial Innovations, and Oxford BioMedica (OXB) announced a global collaboration to develop a first-in-class, long-term therapy fo
Already a subscriber Login

You have read all your free articles, to continue reading subscribe to read the rest of this content.